Gapping up
In reaction to strong earnings/guidance:
- N/A.
M&A news:
- COL +1% (Rockwell Collins to be acquired by United Technologies (UTX) for $140.00 per share)
Other news:
- INSM +107.1% (positive top-line results from Phase 3 CONVERT Study)
- APOP +31.4% (FDA grants orphan drug status to Cellect's ApoGraft for Acute GvHD and Chronic GvHD)
- CDZI +23.2% (announced that the California State Senate set aside AB 1000 following a hearing of its Appropriations subcommittee)
- ORMP +15.6% (reports of successful meeting with FDA regarding its oral insulin)
- BCRX +13% (announces 'positive' results from its APeX-1 Phase 2 Trial in HAE)
- PRQR +3.8% (confirms QRX-421 was granted orphan drug designation by the FDA and EMA)
- PSTI +3.4% (announces that its Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck fracture has been awarded an $8.7 million non-dilutive grant from the Horizon 2020 program)
- ORLY +1.5% (announces additional $1 billion share repurchase authorization)
Analyst comments:
- XOMA +8.7% (upgraded to Outperform at Wedbush)
- LOW +3.1% (initiated with a Buy at BofA/Merrill)
- X +2.6% (upgraded to Buy from Neutral at BofA/Merrill)
- ZEAL +2.4% (initiated with a Overweight at Morgan Stanley)
- SWKS +1.6% (upgraded to Buy from Sell at Citigroup)
- ALXN +0.8% (upgraded to Overweight from Neutral at JP Morgan)
- ORCL +0.6% (initiated with a Outperform at Credit Suisse)
- DIS +0.5% (upgraded to Outperform from Market Perform at Wells Fargo)
